ECSP066968A - Compuestos de metil-aril o heteroaril-amida sustituida - Google Patents

Compuestos de metil-aril o heteroaril-amida sustituida

Info

Publication number
ECSP066968A
ECSP066968A EC2006006968A ECSP066968A ECSP066968A EC SP066968 A ECSP066968 A EC SP066968A EC 2006006968 A EC2006006968 A EC 2006006968A EC SP066968 A ECSP066968 A EC SP066968A EC SP066968 A ECSP066968 A EC SP066968A
Authority
EC
Ecuador
Prior art keywords
heteroaril
amida
aril
methyl
substituted compounds
Prior art date
Application number
EC2006006968A
Other languages
English (en)
Inventor
Tatsuya Yamagishi
Yoshiyuki Okumura
Kazunari Nakao
Hiroki Koike
Yukari Matsumoto
Kana Kon-I
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34982397&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066968(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP066968A publication Critical patent/ECSP066968A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Esta invención proporciona un compuesto de fórmula (I):en la que X representa un átomo de carbono o similar: Y representa imino, o similar: R1 representa un grupo alquilo que tiene de 1 a 6 átomos de carbono o similar; R2 y R3 independientemente representan un átomo de hidrógeno o similar. Estos compuestos son útiles para tratar estados patológicos mediados por prostaglandina tales como el dolor, o similar, en un mamífero. Esta invención también proporciona una composición farmacéutica que comprende el compuesto anterior.
EC2006006968A 2004-05-04 2006-11-01 Compuestos de metil-aril o heteroaril-amida sustituida ECSP066968A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56808804P 2004-05-04 2004-05-04

Publications (1)

Publication Number Publication Date
ECSP066968A true ECSP066968A (es) 2006-12-29

Family

ID=34982397

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006968A ECSP066968A (es) 2004-05-04 2006-11-01 Compuestos de metil-aril o heteroaril-amida sustituida

Country Status (29)

Country Link
US (2) US7534914B2 (es)
EP (1) EP1756042B8 (es)
JP (1) JP4054368B2 (es)
KR (1) KR20070006891A (es)
CN (1) CN1950333A (es)
AP (1) AP2006003785A0 (es)
AR (1) AR048642A1 (es)
AU (1) AU2005238291A1 (es)
BR (1) BRPI0510666A (es)
CA (1) CA2565813C (es)
CR (1) CR8730A (es)
DO (1) DOP2005000071A (es)
EA (1) EA200601847A1 (es)
EC (1) ECSP066968A (es)
ES (1) ES2461265T3 (es)
GT (1) GT200500101A (es)
IL (1) IL178676A0 (es)
MA (1) MA28571B1 (es)
MX (1) MXPA06011555A (es)
NL (1) NL1028947C2 (es)
NO (1) NO20065578L (es)
PA (1) PA8631201A1 (es)
PE (1) PE20060306A1 (es)
SV (1) SV2005002102A (es)
TN (1) TNSN06358A1 (es)
TW (1) TW200536541A (es)
UY (1) UY28877A1 (es)
WO (1) WO2005105732A1 (es)
ZA (1) ZA200608393B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080034205A (ko) * 2005-09-19 2008-04-18 테바 파마슈티컬 인더스트리즈 리미티드 (ｓ)-프레가발린의 신규한 합성을 위한 주요 중간체인 키랄3-카르바모일메틸-5-메틸 헥산산
WO2007077120A1 (de) * 2005-12-28 2007-07-12 Basf Se VERFAHREN ZUR HERSTELLUNG VON (R) - UND (S) -4- (1-AMMONIUMETHYL) BENZOESÄUREMETHYLESTER-SULFAT AUS RACEMISCHEM 4-(l-AMIN0ETHYL)BENZ0ESÄUREMETHYLESTER DURCH LIPASE-KATALYSIERTE ENANTIOSELEKTIVE ACYLIERUNG UND ANSCHLIESSENDEM AUSFÄLLEN MIT SCHWEFELSÄURE
DE102005062966A1 (de) * 2005-12-28 2007-07-05 Basf Ag Verfahren zur Herstellung von (R)- und (S)-4-(Ammoniumethyl)benzoesäuremethylester-sulfat
UY30121A1 (es) 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
CA2660133C (en) * 2006-08-11 2015-10-27 Merck Frosst Canada Ltd. Thiophenecarboxamide derivatives as ep4 receptor ligands
KR20090089868A (ko) 2006-12-15 2009-08-24 글락소 그룹 리미티드 Ｅｐ４ 수용체 작동제로서 벤즈아미드 유도체
EP2172447A4 (en) * 2007-07-03 2011-08-24 Astellas Pharma Inc amide
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
RU2479576C9 (ru) * 2008-05-14 2014-03-10 Астеллас Фарма Инк. Амидное соединение
KR20100107500A (ko) * 2008-06-23 2010-10-05 테바 파마슈티컬 인더스트리즈 리미티드 (ｓ) 또는 (ｒ)-이소-부틸-글루타릭 에스테르의 입체선택적 효소 합성방법
US20110287112A1 (en) 2009-01-30 2011-11-24 Ono Pharmaceutical Co., Ltd. Prostate cancer progression inhibitor and progression inhibition method
CA2754702C (en) 2009-04-22 2016-06-07 Yukinori Take Selective ep4 antagonistic substance for treatment of cancer
JP6152643B2 (ja) * 2010-02-22 2017-06-28 株式会社ＡｓｋＡｔ Ｉｌ−２３媒介疾患を治療するためのｅｐ４受容体拮抗薬の使用
BR112013002484B1 (pt) 2010-09-21 2021-10-13 Eisai R&D Management Co. , Ltd. Composto, composição farmacêutica, e, usos de um composto
CA2820109C (en) 2010-12-10 2018-01-09 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
AU2011372747B2 (en) 2011-07-04 2016-12-22 Rottapharm Biotech S.R.L. Cyclic amine derivatives as EP4 receptor antagonists
KR20140057629A (ko) 2011-08-29 2014-05-13 티코나 엘엘씨 방향족 아마이드 화합물
JP2014525499A (ja) 2011-08-29 2014-09-29 ティコナ・エルエルシー 低い融解温度をもつ耐熱性液晶ポリマー組成物
WO2013032974A1 (en) 2011-08-29 2013-03-07 Ticona Llc Solid-state polymerization of a liquid crystalline polymer
WO2013032967A1 (en) 2011-08-29 2013-03-07 Ticona Llc Cast molded parts formed form a liquid crystalline polymer
TW201319223A (zh) 2011-08-29 2013-05-16 Ticona Llc 高流量液晶聚合物組合物
WO2013032975A1 (en) 2011-08-29 2013-03-07 Ticona Llc Thermotropic liquid crystalline polymer with improved low shear viscosity
WO2013032979A1 (en) 2011-08-29 2013-03-07 Ticona Llc Melt polymerization of low melt viscosity liquid crystalline polymers
KR20140057360A (ko) 2011-08-29 2014-05-12 티코나 엘엘씨 고유동성 액정 중합체 조성물
US8852730B2 (en) 2011-08-29 2014-10-07 Ticona Llc Melt-extruded substrate for use in thermoformed articles
JO3296B1 (ar) * 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
WO2014130275A2 (en) 2013-02-22 2014-08-28 Ticona Llc High performance polymer composition with improved flow properties
JP6340702B2 (ja) 2013-03-19 2018-06-13 株式会社ＡｓｋＡｔ 軟骨疾患を治療するためのｅｐ４受容体拮抗薬の使用
US10391086B2 (en) 2013-03-19 2019-08-27 Askat Inc. Use of EP4 receptor antagonists in the treatment of cartilage disease
WO2014178891A1 (en) 2013-04-30 2014-11-06 Otitopic Inc. Dry powder formulations and methods of use
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫－１ｈ－異喹啉化合物
CN113912988A (zh) 2013-06-07 2022-01-11 提克纳有限责任公司 高强度热致液晶聚合物
HUE039015T2 (hu) 2013-06-12 2018-12-28 Kaken Pharma Co Ltd 4-Alkinil-imidazol-származék és ezt hatóanyagként tartalmazó gyógyszerkészítmény
MX2016007566A (es) * 2013-12-17 2016-10-03 Lilly Co Eli Derivados de amina ciclica de fenoxietilo y su actividad como moduladores de receptor ep4.
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
US10342785B2 (en) 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
JP7253500B2 (ja) 2017-05-18 2023-04-06 イドーシア ファーマシューティカルズ リミテッド ピリミジン誘導体
RS62398B1 (sr) 2017-05-18 2021-10-29 Idorsia Pharmaceuticals Ltd Derivati pirimidina kao modulatori receptora pge2
DK3625222T3 (da) 2017-05-18 2021-10-25 Idorsia Pharmaceuticals Ltd Phenylderivater som pge2-receptormodulatorer
WO2018210987A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as pge2 receptor modulators
EP3625224B1 (en) 2017-05-18 2021-08-04 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives
SK592017A3 (sk) * 2017-07-04 2019-01-08 Saneca Pharmaceuticals A. S. Spôsob prípravy morfínanových zlúčenín
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
WO2019059953A2 (en) 2017-09-22 2019-03-28 Otitopic Inc. DRY POWDER COMPOSITIONS CONTAINING MAGNESIUM STEARATE
CN114075140A (zh) * 2020-08-18 2022-02-22 武汉人福创新药物研发中心有限公司 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在癌症和炎症中的用途
EP4245301A1 (en) 2020-11-13 2023-09-20 ONO Pharmaceutical Co., Ltd. Cancer treatment by combined use of ep4 antagonist and immune checkpoint inhibitor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19648793A1 (de) 1996-11-26 1998-05-28 Basf Ag Neue Benzamide und deren Anwendung
TW523506B (en) * 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
CN1254335A (zh) 1997-04-04 2000-05-24 辉瑞产品公司 烟酰胺衍生物
US6211197B1 (en) * 1998-10-07 2001-04-03 Merck Frosst Canada & Co. Prostaglandin receptor ligands
EP1183235A2 (en) 1999-05-24 2002-03-06 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
US6924391B2 (en) * 2000-05-11 2005-08-02 Bristol-Myers Squibb Company Alpha-amino,-thio,-oxo substituted ketones as phospholipase inhibitors
ES2239203T3 (es) 2001-01-31 2005-09-16 Pfizer Products Inc. Derivados nicotinamida y sus mimeticos como inhibidores de isozimas pde4.
JP4529119B2 (ja) 2001-08-09 2010-08-25 小野薬品工業株式会社 カルボン酸誘導体化合物およびその化合物を有効成分として含有する薬剤
JPWO2003030937A1 (ja) 2001-10-05 2005-01-20 小野薬品工業株式会社 ミトコンドリアルベンゾジアゼピン受容体アンタゴニストからなるストレス疾患の治療剤

Also Published As

Publication number Publication date
EP1756042A1 (en) 2007-02-28
AU2005238291A1 (en) 2005-11-10
WO2005105732A1 (en) 2005-11-10
GT200500101A (es) 2005-12-12
BRPI0510666A (pt) 2007-12-04
NL1028947C2 (nl) 2006-04-10
SV2005002102A (es) 2005-12-13
US20050267170A1 (en) 2005-12-01
ZA200608393B (en) 2008-05-28
PA8631201A1 (es) 2005-11-25
AR048642A1 (es) 2006-05-10
US20090163558A1 (en) 2009-06-25
EP1756042B1 (en) 2014-02-12
CN1950333A (zh) 2007-04-18
EA200601847A1 (ru) 2007-04-27
JP2007536366A (ja) 2007-12-13
KR20070006891A (ko) 2007-01-11
NO20065578L (no) 2007-01-12
CA2565813A1 (en) 2005-11-10
UY28877A1 (es) 2005-12-30
DOP2005000071A (es) 2005-11-30
EP1756042B8 (en) 2014-06-04
US8084476B2 (en) 2011-12-27
TNSN06358A1 (fr) 2008-02-22
US7534914B2 (en) 2009-05-19
WO2005105732A8 (en) 2007-04-19
TW200536541A (en) 2005-11-16
CR8730A (es) 2006-11-30
NL1028947A1 (nl) 2005-11-07
ES2461265T3 (es) 2014-05-19
IL178676A0 (en) 2007-02-11
MA28571B1 (fr) 2007-05-02
PE20060306A1 (es) 2006-04-14
AP2006003785A0 (en) 2006-10-31
CA2565813C (en) 2010-10-26
JP4054368B2 (ja) 2008-02-27
MXPA06011555A (es) 2006-12-15

Similar Documents

Publication Publication Date Title
ECSP066968A (es) Compuestos de metil-aril o heteroaril-amida sustituida
UY28878A1 (es) Compuestos de aril-o heteroarilamida ortosustituidos y composiciones
CO6450621A2 (es) Sulfonamidas nematocidas
ECSP066405A (es) Compuestos de aril o heteroaril amida
ES2193874B1 (es) Compuestos naturales y derivados de estos para la prevencion y el tratamiento de enfermedades cardiovasculares, hepaticas, renales y cosmeticas.
DOP2005000046A (es) Compuestos de acido alfa arilo o heteroaril metil beta piperidino propanoico como antagonistas del receptor orl1
ATE507208T1 (de) Pyrimidin-verbindungen und diese enthaltende zusammensetzungen zur schädlingsbekämpfung
PE20061490A1 (es) Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
GT200500286A (es) Analogos de anilino-pirimidina
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
GB0517191D0 (en) Compounds
AR052866A1 (es) Fenil-metanonas monociclicas sustituidas
UY29412A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos.
ECSP078062A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
PE20021004A1 (es) Derivados de piperidina como inhibidores de la ccr5
UY30673A1 (es) Derivados 6, 7 y 8 sustituidos del acido (3r)-5-oxo-2,3-dihidro-5h-tiazolo[3,2a]piridin-3-carboxilico, composiciones farmacéuticas conteniéndolos y aplicaciones.
EA200800149A1 (ru) 4,5-диарилпиррольные производные, способ их получения и применение в терапии
BR0208812A (pt) Derivados fenil heterociclil éter como inibidores de recaptação de serotonina
UY29048A1 (es) Oxazolidinonas que contienen oxindoles como agentes antibacterianos
UY28497A1 (es) Compuestos de aril o heteroaril amida
AR044996A1 (es) Compuestos de benzotiofeno 2-tio-substituidos, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen
ECSP077225A (es) Oxazolidinonas que contienen oxindoles como agentes antibacterianos
DOP2004000988A (es) Compuestos de aril o teteroaril amida
UY28104A1 (es) Aminoalcoxiindoles